Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses.

Smith W, Tomasec P, Aicheler R, Loewendorf A, Nemčovičová I, Wang EC, Stanton RJ, Macauley M, Norris P, Willen L, Ruckova E, Nomoto A, Schneider P, Hahn G, Zajonc DM, Ware CF, Wilkinson GW, Benedict CA.

Cell Host Microbe. 2013 Mar 13;13(3):324-35. doi: 10.1016/j.chom.2013.02.003.

2.

The structure of cytomegalovirus immune modulator UL141 highlights structural Ig-fold versatility for receptor binding.

Nemčovičová I, Zajonc DM.

Acta Crystallogr D Biol Crystallogr. 2014 Mar;70(Pt 3):851-62. doi: 10.1107/S1399004713033750. Epub 2014 Feb 22.

3.

Structure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactions.

Nemčovičová I, Benedict CA, Zajonc DM.

PLoS Pathog. 2013 Mar;9(3):e1003224. doi: 10.1371/journal.ppat.1003224. Epub 2013 Mar 21.

4.

Inhibition of the TRAIL death receptor by CMV reveals its importance in NK cell-mediated antiviral defense.

Verma S, Loewendorf A, Wang Q, McDonald B, Redwood A, Benedict CA.

PLoS Pathog. 2014 Aug 14;10(8):e1004268. doi: 10.1371/journal.ppat.1004268. eCollection 2014 Aug.

5.

Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141.

Tomasec P, Wang EC, Davison AJ, Vojtesek B, Armstrong M, Griffin C, McSharry BP, Morris RJ, Llewellyn-Lacey S, Rickards C, Nomoto A, Sinzger C, Wilkinson GW.

Nat Immunol. 2005 Feb;6(2):181-8. Epub 2005 Jan 9.

6.

N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.

Dufour F, Rattier T, Shirley S, Picarda G, Constantinescu AA, Morlé A, Zakaria AB, Marcion G, Causse S, Szegezdi E, Zajonc DM, Seigneuric R, Guichard G, Gharbi T, Picaud F, Herlem G, Garrido C, Schneider P, Benedict CA, Micheau O.

Cell Death Differ. 2017 Mar;24(3):500-510. doi: 10.1038/cdd.2016.150. Epub 2017 Feb 10.

7.

Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity.

Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar PV, Johnson DC, Cosman D.

J Exp Med. 2003 Jun 2;197(11):1427-39.

8.

Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112.

Prod'homme V, Sugrue DM, Stanton RJ, Nomoto A, Davies J, Rickards CR, Cochrane D, Moore M, Wilkinson GW, Tomasec P.

J Gen Virol. 2010 Aug;91(Pt 8):2034-9. doi: 10.1099/vir.0.021931-0. Epub 2010 Apr 21.

9.

Human cytomegalovirus UL141 protein interacts with CELF5 and affects viral DNA replication.

Zou F, Lu ZT, Wang S, Wu S, Wu YY, Sun ZR.

Mol Med Rep. 2018 Mar;17(3):4657-4664. doi: 10.3892/mmr.2018.8419. Epub 2018 Jan 10.

PMID:
29328469
10.

UL40-mediated NK evasion during productive infection with human cytomegalovirus.

Wang EC, McSharry B, Retiere C, Tomasec P, Williams S, Borysiewicz LK, Braud VM, Wilkinson GW.

Proc Natl Acad Sci U S A. 2002 May 28;99(11):7570-5.

11.

Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk--a pivotal role of HMGB1.

Melki MT, Saïdi H, Dufour A, Olivo-Marin JC, Gougeon ML.

PLoS Pathog. 2010 Apr 15;6(4):e1000862. doi: 10.1371/journal.ppat.1000862.

12.

The tiers and dimensions of evasion of the type I interferon response by human cytomegalovirus.

Amsler L, Verweij M, DeFilippis VR.

J Mol Biol. 2013 Dec 13;425(24):4857-71. doi: 10.1016/j.jmb.2013.08.023. Epub 2013 Sep 5. Review.

13.

Human leukocyte antigen E in human cytomegalovirus infection: friend or foe?

Gong F, Song S, Lv G, Pan Y, Zhang D, Jiang H.

Acta Biochim Biophys Sin (Shanghai). 2012 Jul;44(7):551-4. doi: 10.1093/abbs/gms032. Epub 2012 May 9. Review.

PMID:
22576308
14.

CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity.

Corrales-Aguilar E, Hoffmann K, Hengel H.

Semin Immunopathol. 2014 Nov;36(6):627-40. doi: 10.1007/s00281-014-0448-2. Epub 2014 Oct 7. Review.

PMID:
25288477
15.

A Prominent Role of the Human Cytomegalovirus UL8 Glycoprotein in Restraining Proinflammatory Cytokine Production by Myeloid Cells at Late Times during Infection.

Pérez-Carmona N, Martínez-Vicente P, Farré D, Gabaev I, Messerle M, Engel P, Angulo A.

J Virol. 2018 Apr 13;92(9). pii: e02229-17. doi: 10.1128/JVI.02229-17. Print 2018 May 1.

16.

Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses.

Wang ECY, Pjechova M, Nightingale K, Vlahava VM, Patel M, Ruckova E, Forbes SK, Nobre L, Antrobus R, Roberts D, Fielding CA, Seirafian S, Davies J, Murrell I, Lau B, Wilkie GS, Suárez NM, Stanton RJ, Vojtesek B, Davison A, Lehner PJ, Weekes MP, Wilkinson GWG, Tomasec P.

Proc Natl Acad Sci U S A. 2018 May 8;115(19):4998-5003. doi: 10.1073/pnas.1720950115. Epub 2018 Apr 24.

17.

Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141.

Hsu JL, van den Boomen DJ, Tomasec P, Weekes MP, Antrobus R, Stanton RJ, Ruckova E, Sugrue D, Wilkie GS, Davison AJ, Wilkinson GW, Lehner PJ.

PLoS Pathog. 2015 Apr 14;11(4):e1004811. doi: 10.1371/journal.ppat.1004811. eCollection 2015 Apr.

18.

Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein.

Welte SA, Sinzger C, Lutz SZ, Singh-Jasuja H, Sampaio KL, Eknigk U, Rammensee HG, Steinle A.

Eur J Immunol. 2003 Jan;33(1):194-203.

19.

Noncytotoxic inhibition of cytomegalovirus replication through NK cell protease granzyme M-mediated cleavage of viral phosphoprotein 71.

van Domselaar R, Philippen LE, Quadir R, Wiertz EJ, Kummer JA, Bovenschen N.

J Immunol. 2010 Dec 15;185(12):7605-13. doi: 10.4049/jimmunol.1001503. Epub 2010 Nov 8.

20.

Human cytomegalovirus infection elicits new decidual natural killer cell effector functions.

Siewiera J, El Costa H, Tabiasco J, Berrebi A, Cartron G, Le Bouteiller P, Jabrane-Ferrat N.

PLoS Pathog. 2013;9(4):e1003257. doi: 10.1371/journal.ppat.1003257. Epub 2013 Apr 4. Erratum in: PLoS Pathog. 2013 May;9(5). doi:10.1371/annotation/94476def-de2e-4a6e-b0c2-2f2d2ccae784. Bouteiller, Philippe [corrected to Le Bouteiller, Philippe].

Supplemental Content

Support Center